BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 466 filers reported holding BIO-TECHNE CORP in Q1 2021. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $9,804,000 | +1.4% | 25,670 | -15.7% | 0.53% | -7.5% |
| Q4 2020 | $9,669,000 | +66.6% | 30,450 | +30.0% | 0.58% | +47.2% |
| Q3 2020 | $5,804,000 | +3.8% | 23,430 | +10.7% | 0.39% | -3.2% |
| Q2 2020 | $5,590,000 | +38.6% | 21,170 | -0.5% | 0.40% | +23.9% |
| Q1 2020 | $4,033,000 | -36.5% | 21,270 | -26.5% | 0.33% | -25.5% |
| Q4 2019 | $6,350,000 | +101.6% | 28,930 | +91.5% | 0.44% | +96.9% |
| Q2 2019 | $3,150,000 | -64.7% | 15,110 | -66.4% | 0.22% | -60.0% |
| Q1 2019 | $8,922,000 | +64.9% | 44,935 | +20.2% | 0.56% | +34.1% |
| Q4 2018 | $5,411,000 | -31.2% | 37,390 | -3.0% | 0.42% | -17.1% |
| Q3 2018 | $7,869,000 | +76.0% | 38,555 | +27.6% | 0.50% | +73.7% |
| Q2 2018 | $4,470,000 | -42.2% | 30,215 | -41.0% | 0.29% | -47.5% |
| Q1 2018 | $7,736,000 | +39.3% | 51,215 | +19.5% | 0.55% | +39.6% |
| Q4 2017 | $5,554,000 | +35.9% | 42,870 | +26.8% | 0.39% | +28.3% |
| Q3 2017 | $4,088,000 | +40.4% | 33,820 | +36.5% | 0.31% | +38.3% |
| Q2 2017 | $2,911,000 | – | 24,775 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |